Loading clinical trials...
Loading clinical trials...
This study was designed to provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic renal failure due to autosomal dominant polycystic kidney disease (ADPKD).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Royan Institute
NCT07161037 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT04939935 · Autosomal Dominant Polycystic Kidney Disease
NCT07454174 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06902558 · Autosomal Dominant Polycystic Kidney Disease
NCT07260071 · Autosomal Dominant Polycystic Kidney Disease (ADPKD
Royan Institute
Tehran
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions